Peer-reviewed veterinary case report
Minimal residual disease predicts chemo outcome in dogs with B-cell
By Sato, Masahiko et al.·Published in Veterinary journal (London, England : 1997)·2013·Department of Veterinary Internal Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma.
- Species:
- dog
Plain-English summary
A group of 36 dogs with high-grade B-cell lymphoma were treated with a specific chemotherapy protocol for six months. During treatment, researchers looked for minimal residual disease (MRD), which indicates how many cancer cells remain in the body. By week 11, 14 dogs had no detectable MRD and lived significantly longer without disease progression compared to the 17 dogs that still had MRD. This study highlights the importance of monitoring MRD during early chemotherapy to better understand a dog's prognosis.
People also search for: dog lymphoma treatment · high-grade B-cell lymphoma in dogs · chemotherapy for dogs with cancer
Abstract
The prognostic significance of minimal residual disease (MRD) in the early phases of chemotherapy was examined in 36 dogs with multicentric high-grade B-cell lymphoma. Sequences of immunoglobulin heavy chain (IgH) gene fragments from lymphoma cells were amplified and used to design allele-specific primers and probes for real-time PCR. The dogs were treated with a 6-month modified version of the University of Wisconsin-Madison chemotherapy protocol (UW-25) and evaluated for the MRD level at weeks 6 and 11 of UW-25. Of the 31 dogs that remained on the protocol at week 11, 14 were found to be MRD negative (<10tumour cells/10(5) peripheral blood mononuclear cells [PBMCs]), whereas the other 17 were MRD positive (⩾10tumour cells/10(5) PBMCs). The progression-free survival of the dogs with MRD-negative status at week 11 (median, 337days) was significantly longer than that of the MRD-positive dogs at the same time point (median, 196days) (P=0.0002). These results indicate the clinical significance of MRD as a prognostic marker in the early phase of chemotherapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22909955/